ASX:DXB Dimerix (DXB) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free DXB Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield5.16%Price TargetN/A Stock AnalysisStock Analysis Get Dimerix alerts: Email Address Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About DimerixDimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. The company is headquartered in Fitzroy, Australia.Read More Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. DXB Stock News HeadlinesApril 16, 2024 | afr.comDimerix LimitedApril 8, 2024 | finance.yahoo.comCompanies Like Dimerix (ASX:DXB) Could Be Quite RiskyApril 28, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 8, 2024 | finance.yahoo.comInvestors ignore increasing losses at Dimerix (ASX:DXB) as stock jumps 236% this past weekApril 8, 2024 | finance.yahoo.comShareholders Will Likely Find Dimerix Limited's (ASX:DXB) CEO Compensation AcceptableApril 8, 2024 | finance.yahoo.comCalculating The Intrinsic Value Of Dimerix Limited (ASX:DXB)August 29, 2022 | finance.yahoo.comTrade Alert: Peter Meurs At Dimerix Limited (ASX:DXB), Has Just Spent AU$3.5m Buying 66% More SharesAugust 29, 2022 | finance.yahoo.comHere's Why We're Watching Dimerix's (ASX:DXB) Cash Burn SituationApril 28, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)August 29, 2022 | finance.yahoo.comWe Think Dimerix (ASX:DXB) Needs To Drive Business Growth CarefullySee More Headlines Receive DXB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dimerix and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:DXB CUSIPN/A CIKN/A Webdimerix.com Phone1.212.250.8024FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,870,000.00 Net Margins-119.20% Pretax MarginN/A Return on Equity-330.96% Return on Assets-63.63% Debt Debt-to-Equity Ratio83.19 Current Ratio4.84 Quick Ratio7.91 Sales & Book Value Annual Sales$9.12 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares548,600,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.51 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Nina Webster B.Sc.M.B.A., M.IP.Law, MBA, Ph.D., CEO, MD & DirectorMr. Hamish George B.Com.C.A., CFO & Company SecretaryDr. David Everett Fuller BPharm (Age 60)M.D., MBBS, Chief Medical Officer Mr. Kevin Donald George Pfleger BA (Hons)MA, Ph.D., Chief Scientific AdvisorMr. Robert ShepherdChief Commercialisation OfficerKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersNina WebsterBought 33,000 shares on 3/27/2024Total: $10,230.00 ($0.31/share)Nina WebsterSold 93,750 sharesTotal: $11,812.50 ($0.13/share)Nina WebsterSold 2,052,956 sharesTotal: $283,307.93 ($0.14/share)Sonia PoliSold 11,334 sharesTotal: $4,533.60 ($0.40/share)Nina WebsterSold 187,500 sharesTotal: $15,000.00 ($0.08/share) This page (ASX:DXB) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dimerix Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
